Artivion, Inc. (NYSE:AORT) Director Anthony B. Semedo Sells 9,709 Shares
Artivion, Inc. (NYSE:AORT) Director Anthony B. Semedo sold 9,709 shares at an average price of $0.99 on August 13th, totaling $9,627.91. Post-transaction, he owns 34,159 shares valued at approximately $33,633.41. The SEC filing disclosed this sale. The stock traded at $0.72 recently, with a market cap of $0.07 billion. Analysts have upgraded their target prices, with ratings mostly at 'buy'. Institutional investors hold 86.37% of shares, with notable increases in holdings from First Eagle Investment Management and Wasatch Advisors in the last quarter.
Artivion, Inc. (NYSE:AORT - Get Free Report) Director Anthony B. Semedo sold 9,709 shares of the firm's stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $24.99, for a total transaction of $242,627.91. Following the completion of the sale, the director now owns 34,159 shares in the company, valued at $853,633.41. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Artivion Price Performance
AORT stock traded up $1.21 during trading on Thursday, reaching $25.72. The company's stock had a trading volume of 87,208 shares, compared to its average volume of 226,466. The company's fifty day moving average is $25.45 and its 200-day moving average is $22.28. Artivion, Inc. has a 1 year low of $12.16 and a 1 year high of $29.24. The company has a market capitalization of $1.07 billion, a P/E ratio of -102.13 and a beta of 1.75. The company has a quick ratio of 4.26, a current ratio of 6.04 and a debt-to-equity ratio of 1.07.
Institutional Investors Weigh In On Artivion
Hedge funds and other institutional investors have recently made changes to their positions in the company. First Eagle Investment Management LLC grew its holdings in shares of Artivion by 8.1% during the first quarter. First Eagle Investment Management LLC now owns 570,242 shares of the company's stock valued at $12,066,000 after buying an additional 42,705 shares during the last quarter. Wasatch Advisors LP increased its position in shares of Artivion by 108.8% in the first quarter. Wasatch Advisors LP now owns 1,083,568 shares of the company's stock valued at $22,928,000 after buying an additional 564,549 shares in the last quarter. Vanguard Group Inc. lifted its stake in Artivion by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 2,664,855 shares of the company's stock valued at $56,388,000 after buying an additional 33,982 shares in the last quarter. Tidal Investments LLC acquired a new stake in Artivion during the 1st quarter worth $257,000. Finally, Allspring Global Investments Holdings LLC boosted its holdings in shares of Artivion by 291.3% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 5,580 shares of the company's stock worth $118,000 after purchasing an additional 4,154 shares during the last quarter. Hedge funds and other institutional investors own 86.37% of the company's stock.
Analyst Ratings Changes
A number of analysts recently commented on AORT shares. Lake Street Capital boosted their target price on Artivion from $28.00 to $30.00 and gave the company a "buy" rating in a research report on Tuesday, July 2nd. Needham & Company LLC reaffirmed a "buy" rating and set a $30.00 target price on shares of Artivion in a report on Friday, August 9th. Stifel Nicolaus lifted their target price on shares of Artivion from $25.00 to $28.00 and gave the company a "buy" rating in a research report on Friday, August 9th. Finally, Oppenheimer increased their target price on shares of Artivion from $25.00 to $30.00 and gave the company an "outperform" rating in a report on Friday, August 9th.
View Our Latest Stock Report on Artivion
About Artivion
(Get Free Report)Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.
Featured Articles
- Five stocks we like better than Artivion
- Investing in the High PE Growth Stocks
- Michael Burry's Alibaba Bet and the Broader Market Implications
- Conference Calls and Individual Investors
- Jeff Brown's Exegesis AI Stock Picks
- How to Invest in Biotech Stocks
- Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
→ What Is the $7,882 Stimulus Payment 2024? (From Angel Publishing) (Ad)
Should you invest $1,000 in Artivion right now?
Before you consider Artivion, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Artivion wasn't on the list.
While Artivion currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
